Compare Huntington Bancshares Incorporated (HBAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs 10X Genomics Inc — how do they compare? Huntington Bancshares Incorporated trades at $15.29 (market cap $31.04B), while 10X Genomics Inc trades at $82.23 (market cap $10.07B). The key difference: Huntington Bancshares Incorporated is far larger — about 3.1× 10X Genomics Inc's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and 10X Genomics Inc for 92 Days on average.
| HBAN | TXG | |
|---|---|---|
Market Cap | $31.04B | $10.07B |
Volume | 23,864,172 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $19.27 | $97.74 |
52-Week Low | $15.02 | $11.48 |
Typical Hold Time | 52 Days | 92 Days |
Enterprise Value | $49.57B | $9.59B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.28, up 0.73% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bearish technical signal with key support at $15 and resistance at $16, while fundamentals show a P/E of 11.82 and net income margin of 24.77%. Recent news highlights a cut in 2027 earnings outlook due to interest rate pressures, though the company maintains shareholder returns via dividends and buybacks.
The outlook for HBAN is cautious, with near-term headwinds from margin compression and loan growth challenges offset by a solid balance sheet and analyst consensus price target of $19.60. Risks include persistent interest rate pressures and competitive lending markets, but the stock offers value appeal with a dividend yield and institutional support.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
